Merck's new specialty, pharma & infectious diseases chief Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 27 February, 2026

Rethink what's possible for mature products — Download the playbook sponsored by Cencora

presented by Health Eco­nom­ic Out­comes of the On­co­type DX Breast Re­cur­rence Test at a Pop­u­la­tion Health Lev­el

spotlight Who’s leading LGBTQ+ inclusion in biopharma? Nominate them for Endpoints’ annual report

news In Focus Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future Peer Review Doug Ingram’s uneven legacy at Sarepta; Merck splits human health business, brings in Sanofi exec •  Doug Ingram’s force of will meets its match as Sarepta CEO plans to depart

Mar 03 12:00 pm ET Innovation in biopharmaceuticals: A conversation with Fujifilm leaders sponsored by Fujifilm Mar 24 11:30 am ET From structure to selectivity: Federated AI for collaborative binding affinity prediction sponsored by Rhino Federated Computing

CGT has fresh momentum from new FDA frameworks and pharma deals, but do the latest advances in science, manufacturing, and regulation actually solve the core challenges? We’re asking the hard questions — join us.

endpoints pharma FDA probes internal Prasad complaints with outside help Voucher holder Boehringer wins sped-up approval for first-line use of lung cancer drug Senate hearing stirs concerns over FDA’s handling of rare disease drugs Viatris plans to lay off up to 10% of staff, discloses Indian factory fire  DOJ urges Supreme Court to undo revival of Hikma ‘skinny label’ case

in case you missed it 1. OrbiMed jumps to number one on the top 100 list of biotech venture investors 2. Protagonist to opt out of Takeda profit-sharing deal, will receive $400M in cash 3. News Briefing AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug 4. Lilly’s GLP-1 pill beats Novo’s in diabetes trial, but has more side effects 5. Japanese conglomerate Asahi Kasei to buy German antiviral biotech Aicuris for $920M 6. FDA to Give Staff Bonuses for Speeding Up Drug Reviews